I last analyzed Paycom Software, Inc. (PAYC) in my November 7, 2025 post at which time the Q3 and YTD2025 results were the most recent. Although the Q4 and FY2025 results were released on February 11, the Form 10-K was only made available shortly before I departed on a ski vacation. Although my ~$227.0705 average [...]

The post

I last reviewed Paychex (PAYX) in this November 5, 2025 post at which time the most current financial information was for Q1 2026. At the time, shares were trading at ~$115.77. As luck would have it, PAYX continues to generate strong results but the share price as I compose this post on March 26, 2026 [...]

The post

  In my November 21, 2025 post I reviewed Veeva (VEEV) following the release of its Q3 and YTD2026 results. I subsequently provided updates on January 6 and January 18, 2026 that are accessible through the FFJ Archives. The Q4 and FY2026 results are now available thus prompting me to revisit this existing holding. Business [...]

The post

In my December 20, 2025 post I look at Cintas' (CTAS) Q2 and YTD2026 results. I also reference my December 8, 2025 post in which I raise the question of whether CTAS could take another run at trying to acquire Unifirst (UNF) - its largest US competitor. On December 22, 2025, CTAS disclosed its proposal [...]

The post

  When I reviewed CME Group (CME) in my October 25, 2025 post, it had recently released its Q3 and YTD2025 results. In that post I express my optimism that CME will start repurchasing shares. Given this optimism I purchased an additional 100 shares @ $266.875 on January 6, 2026 in a ‘Core’ account in [...]

The post